Soligenix Advances Thermostable Vaccine Development for Bundibugyo Virus Amid Ongoing Outbreak

Soligenix (SNGX) is making significant strides in the development of a thermostable vaccine against the Bundibugyo virus, invaluable amidst the ongoing outbreak. Collaborating with Dr. Axel Lehrer from the University of Hawaiʻi at Mānoa, Soligenix applies its innovative ThermoVax® technology to create effective and easily transportable vaccines. This strategic emphasis on thermostable formulations enables vaccines to be shipped at ambient temperatures, which is crucial for enhancing vaccination logistics, particularly in resource-limited settings such as Africa. The company's prior work with vaccines against Ebola, Sudan, and Marburg viruses highlights its strong foundation and expertise in the field, reinforcing the importance of accessibility and logistics in combatting infectious diseases.

Critical Research Bolsters Vaccine Development

The recent confirmation of the compatibility of a critical Bundibugyo virus antigen by Dr. Lehrer's research adds confidence to the rapid development of an effective protein-based subunit vaccine. Soligenix’s previously-created vaccines have demonstrated up to 100% protection in non-human primates and potent immune responses in mice. By utilizing the ThermoVax® platform, the company aims to deliver a vaccine that requires only reconstitution with sterile water before administration, a simplification that can greatly enhance distribution efforts in regions with challenging storage conditions. This development aligns with Soligenix's commitment to addressing emerging viral threats with innovative solutions.

Future Prospects and Strategic Importance

Dr. Christopher J. Schaber, President and CEO of Soligenix, emphasizes that the advancements in protein subunit vaccines position them as a competitive alternative to traditional approaches that rely heavily on cold storage. With adequate funding and support, Soligenix is optimistic about the future of its Bundibugyo virus vaccine, exploring potential combinations with other existing vaccines to strengthen public health responses. This ambitious endeavor not only strives to protect against the Bundibugyo virus but also reaffirms Soligenix's dedication to contributing significantly to global health initiatives in the face of pandemic challenges.